Corporate News     16-Oct-24
Wockhardt files its Aspart insulin injection with DCGI

Wockhardt announced the filing of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). This significant milestone reflects Wockhardt's ongoing commitment to address the growing diabetes epidemic both in India and globally.

Wockhardt's Aspart insulin injection (ASPARAPID™) is an indigenously developed product, underscoring the company's end-to-end capabilities in research & development, clinical studies, scale up and manufacturing of biosimilars products. By leveraging integrated infrastructure and expertise, Wockhardt has completed all stages of ASPARAPID™ development - from research to production through in-house development. It offers enhanced quality and accessibility for patients. ASPARAPID™ will be available in cartridges, vials, and prefilled disposable pens, offering flexibility to the patients for management of diabetes. The market size of Aspart in India is currently estimated over Rs 260 crore with only 2 players and is expected to grow significantly in the coming years.

“We are proud of adding another feather in our diabetes biosimilars portfolio through filing of insulin Aspart injection in a market that has limited competition. This reinforces Wockhardt's ability to develop and manufacture complex biosimilars domestically,” said Dr. Habil Khorakiwala, Founder Chairman of Wockhardt. “Our aim is to make world-class diabetes care accessible to patients in India and globally and to contribute meaningfully to the management of diabetes.”

Wockhardt is also developing additional insulin analogs and GLP-1 agonists as part of its comprehensive strategy to provide advanced diabetes care solutions. The introduction of these products will further strengthen Wockhardt's diabetes portfolio, offering patients more effective treatment options for managing their condition.

Previous News
  Wockhardt to conduct board meeting
 ( Corporate News - 08-Nov-24   16:42 )
  Wockhardt slumps on launching QIP at discount
 ( Hot Pursuit - 07-Nov-24   14:38 )
  Wockhardt files its Aspart insulin injection with DCGI
 ( Corporate News - 16-Oct-24   09:21 )
  Wockhardt's once-a-day antibiotic drug 'WCK 6777' successfully concludes Phase I study
 ( Corporate News - 07-Oct-24   14:59 )
  Wockhardt announces cessation of director
 ( Corporate News - 30-Sep-24   18:20 )
  Wockhardt's investigational drug, Zaynich™ demonstrates its ability to manage complex infections
 ( Corporate News - 19-Sep-24   09:15 )
  Wockhardt allots 8,610 equity shares under ESOS
 ( Corporate News - 26-Aug-24   17:00 )
  Wockhardt reports consolidated net loss of Rs 14.00 crore in the June 2024 quarter
 ( Results - Announcements 09-Aug-24   15:43 )
  Wockhardt to table results
 ( Corporate News - 08-Aug-24   10:21 )
  Sensex climbs 380 pts; European mkt opens higher
 ( Market Commentary - Mid-Session 01-Jul-24   13:33 )
  Wockhardt Ltd leads gainers in 'A' group
 ( Hot Pursuit - 01-Jul-24   12:00 )
Other Stories
  CAMS and KFin Technologies form JV for MF Central
  11-Nov-24   19:02
  L&T Technology Services signs definitive agreements to acquire Intelliswift
  11-Nov-24   19:00
  Balmer Lawrie announces its foray into rail logistics
  11-Nov-24   18:55
  ICRA announces cessation of directors
  11-Nov-24   18:52
  Board of Goodyear India approves change in chairperson
  11-Nov-24   18:50
  Harsha Engineers International appoints director
  11-Nov-24   18:49
  Britannia Industries approves appointment of Jehangir Nusli Wadia on Board
  11-Nov-24   18:46
  Board of EPL approves change in directorate
  11-Nov-24   18:44
  Shree Digvijay Cement Co. allots 4.07 lakh equity shares under ESOP
  11-Nov-24   18:42
  Shriram Finance allots 24,197 equity shares under ESOS
  11-Nov-24   18:41
Back Top